News | November 10, 2021
India Pharmaceutical Market grows 5% in October 2021
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
The company has operations in North America, Asia, and Europe,
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The software enables real-time communication between patients, caregivers, physicians, and pharmacists and each cartridge in the device has a unique, traceable serial number registered to the patient
The company reports revenue growth of 26% and PAT growth of 21% YoY
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Deal signed with AOP Orphan for US commercial rights
Subscribe To Our Newsletter & Stay Updated
